Hindi nagbibigay ng serbisyo ang XM sa mga residente ng Estados Unidos.

Hindi nagbibigay ng serbisyo ang XM sa mga residente ng Estados Unidos.
B
B

Biomarin

Balita

Reuters - 1 buwan ang nakaraan

BridgeBio climbs on positive mid-stage trial for genetic condition treatment

BUZZ-BridgeBio climbs on positive mid-stage trial for genetic condition treatment ** Shares of drug developer BridgeBio Pharma BBIO.O rise ~8% to $31.29 premarket ** Co says its oral therapy infigratinib showed significant improvement in body proportionality in patients with achondroplasia, during a mid-stage trial ** Achondroplasia is a genetic bo
B
Reuters - 2 buwan ang nakaraan

U.S. Bath & Body Works, Under Armour, Viking Therapeutics

U.S. RESEARCH ROUNDUP-Bath & Body Works, Under Armour, Viking Therapeutics May 17 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Bath & Body Works, Under Armour and Viking Therapeutics, on Friday. HIGHLIGHTS * Advanced Drainage Systems Inc WMS.N : Barclays raises target price to $202 from $189 * Bath & Body Works Inc BBWI.N : JP Morgan raises to neutral from underweight * Tanger Inc SKT.N : Scotiabank raises to sect
B
C
G
M
T
A
A
C
D
T
Reuters - 2 buwan ang nakaraan

Third Point Llc Takes Share Stake In Alphabet, Advance Auto Parts; Dissolves In U.S. Steel, Dupont

BRIEF-Third Point Llc Takes Share Stake In Alphabet, Advance Auto Parts; Dissolves In U.S. Steel, Dupont May 15 (Reuters) - Third Point LLC: THIRD POINT LLC TAKES SHARE STAKE OF 3.0 MILLION SHARES OF CLASS A CAPITAL STOCK - SEC FILING THIRD POINT LLC TAKES SHARE STAKE OF 1.5 MILLION SHARES IN ADVANCE AUTO PARTS INC THIRD POINT LLC DISSOLVES SHARE S
B
G
U
M
A
Reuters - 2 buwan ang nakaraan

U.S. Akoya Biosciences, Boston Beer Company, Victory Capital Holdings

U.S. RESEARCH ROUNDUP- Akoya Biosciences, Boston Beer Company, Victory Capital Holdings May 14 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Akoya Biosciences, Boston Beer Company and Victory Capital Holdings on Tuesday. HIGHLIGHTS * Akoya Biosciences Inc AKYA.O : Canaccord Genuity cuts target price to $6 from $10 * Boston Beer Company Inc SAM.N : Jefferies raises target price to $360 from $335 * Fortrea Holdings I
B
C
A
A
C
Reuters - 2 buwan ang nakaraan

Biomarin's Says New Data For Vosoritide Presented At Pediatric Endocrine Society (PES) Annual Meeting

BRIEF-Biomarin's Says New Data For Vosoritide Presented At Pediatric Endocrine Society (PES) Annual Meeting May 4 (Reuters) - Biomarin Pharmaceutical Inc BMRN.O : NEW DATA FOR BIOMARIN'S VOXZOGO® (VOSORITIDE) FOR MULTIPLE GROWTH-RELATED CONDITIONS IN CHILDREN PRESENTED AT PEDIATRIC ENDOCRINE SOCIETY (PES) ANNUAL MEETING Source text for Eikon: ID:n
B
Reuters - 3 buwan ang nakaraan

U.S. STOCKS Loar, Regeneron, Intel

BUZZ-U.S. STOCKS ON THE MOVE-Loar, Regeneron, Intel Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stocks slumped on Thursday as most megacaps fell after Meta Platforms' quarterly results, while sentiment was shaken amid signs of persistent inflation that dampened hopes of the Federal Reserve easing monetary policy anytime soon.
A
B
B
B
C
C
G
I
M
N
N
P
R
T
L
T
U
U
D
R
S
T
W
C
D
L
T
Reuters - 3 buwan ang nakaraan

U.S. STOCKS Viking, Alphabet, Dover

BUZZ-U.S. STOCKS ON THE MOVE-Viking, Alphabet, Dover Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stocks were sharply lower on Thursday, dragged down by growth stocks after dour quarterly results from Meta Platforms, while signs of persistent inflation dampened hopes of the Federal Reserve cutting interest rates anytime soon.
A
B
B
B
C
G
M
M
N
N
R
T
L
U
U
D
R
S
T
W
C
D
T
Reuters - 3 buwan ang nakaraan

BioMarin falls after Q1 revenue miss

BUZZ-BioMarin falls after Q1 revenue miss ** Shares of drugmaker BioMarin Pharmaceutical BMRN.O falls ~10.8% to $81.35 ** Co reported Q1 revenue of $648.80 mln after market close on Wednesday, missing analysts' average expectation of $651.80 mln - LSEG data ** BMRN posts quarterly adj. profit of 71 cents/shr vs analysts' average estimates of 34 cen
B
Reuters - 3 buwan ang nakaraan

U.S. Doximity, Monster Beverage, ServiceNow

U.S. RESEARCH ROUNDUP- Doximity, Monster Beverage, ServiceNow April 25 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Doximity, Monster Beverage and ServiceNow, on Thursday. HIGHLIGHTS * Doximity Inc DOCS.N : JP Morgan raises to neutral from underweight * Monster Beverage Corp MNST.O : JP Morgan cuts to neutral from overweight * ServiceNow Inc NOW.N : HSBC raises target price to $905 from $874 * Trustmark Corp TRMK.
A
A
A
B
B
B
C
C
H
M
L
S
A
A
C
Reuters - 3 buwan ang nakaraan

Biomarin Pharmaceutical Inc reports results for the quarter ended in March - Earnings Summary

Biomarin Pharmaceutical Inc reports results for the quarter ended in March - Earnings Summary Biomarin Pharmaceutical Inc BMRN.OQ reported quarterly adjusted earnings of 46 cents​​ per share for the quarter ended in March, higher than the same quarter last year, when the company reported EPS of 27 cents. The mean expectation of twenty three analysts for the quarter was for earnings of 35 cents per share.
B
Reuters - 3 buwan ang nakaraan

Biomarin Pharmaceutical Q1 EPS USD 0.46

BRIEF-Biomarin Pharmaceutical Q1 EPS USD 0.46 Apr 24 (Reuters) - Biomarin Pharmaceutical Q1 revenue USD 648.8 million vs. IBES estimate USD 651.8 million. Q1 adjusted EPS USD 0.71 vs. IBES estimate USD 0.34 Q1 basic EPS USD 0.47 Q1 net income USD 88.7 million vs. IBES estimate USD 62.6 million
B
Reuters - 3 buwan ang nakaraan

Biomarin Pharmaceutical Inc <BMRN.OQ> expected to post earnings of 35 cents a share - Earnings Preview

Biomarin Pharmaceutical Inc expected to post earnings of 35 cents a share - Earnings Preview Biomarin Pharmaceutical Inc BMRN.OQ BMRN.O is expected to show a rise in quarterly revenue when it reports results on April 24 for the period ending March 31 2024 The Novato California-based company is expected to report a 9.3% increase in revenue to $651.788 million from $596.42 million a year ago, according to the mean estimate from 22 analysts, based on LSEG data.
B
Reuters - 3 buwan ang nakaraan

U.S. American Express, Philip Morris, Royal Gold

U.S. RESEARCH ROUNDUP-American Express, Philip Morris, Royal Gold April 22 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including American Express, Philip Morris and Royal Gold, on Monday. HIGHLIGHTS * American Express Co AXP.N : TD Cowen raises target price to $225 from $221 * Philip Morris PM.N : Jefferies raises target price to $101 from $98 * PPG Industries Inc PPG.N : Evercore ISI cuts to in line from outperform * Roya
A
A
A
A
B
B
C
C
D
E
H
I
L
F
U
A
A
C

Kundisyon

Mga Patok na Assets

Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.

Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.

Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.

Babala sa Risk: Maaaring malugi ang iyong kapital. Maaaring hindi nababagay sa lahat ang mga produktong naka-leverage. Mangyaring isaalang-alang ang aming Pahayag sa Risk.